618-P: Association between Time-in-Range and A1C in Basal Insulin-Treated People with Type 2 Diabetes
Bibliographic record
Abstract
Background: The randomized, crossover SWITCH PRO trial demonstrated increased time in range (TIR) with insulin degludec vs. insulin glargine U100 in basal insulin-treated type 2 diabetes (T2D). TIR as an emerging glycemic metric, captured by intermittently scanned continuous glucose monitoring (isCGM), may provide a more comprehensive picture of glycemic control than A1C alone. More evidence is required to confidently associate these metrics in insulin-treated T2D. This post hoc analysis of SWITCH PRO aimed to evaluate correlation between TIR and A1C in this less studied population.Methods: Correlation between absolute values for TIR (70-180 mg/dL) and A1C at baseline (BL) and at the end of maintenance periods 1 (M1) (week 18) and 2 (M2) (week 36) was assessed using the Spearman correlation coefficient (rs).Results: Scatter plots showed a moderately positive linear correlation between TIR and A1C (Figure) at BL (rs -0.541), which improved with treatment intensification (M1: rs -0.594; M2: rs -0.596). Improved glycemic control following treatment intensification was signified by lower A1C values and greater TIR: 50% TIR corresponded to an estimated A1C 7.9% at BL, 7.8% in M1 and 7.8% in M2; 70% TIR corresponded to an estimated A1C 7.5% at BL, 7.2% in M1 and 7.2% in M2.Discussion: We observed a correlation between TIR and A1C in T2D treated with basal insulin. Improvement in TIR could be translated to lower A1C levels.View largeDownload slideView largeDownload slide DisclosureR. Goldenberg: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Consultant; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Research Support; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Speaker’s Bureau; Self; Agora , Amgen Canada, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., CCRN, CHRC, CMS Canada, CSEM, Eli Lilly and Company, EOCI , HLS Therapeutics Inc., Inceptus, Janssen Pharmaceuticals, Inc., liV Medical Education Agency, Master Clinician Alliance , Medplan, Merck & Co., Inc., Mylan N. V., Novo Nordisk Canada Inc., Sanofi, Servier Laboratories, STA Communications Inc., TKTWG, Valeant . V. R. Aroda: Consultant; Self; Applied Therapeutics, Duke, Novo Nordisk, Pfizer Inc., Sanofi, Employee; Spouse/Partner; Janssen , Merck , Research Support; Self; Applied Therapeutics, Eli Lilly and Company, Fractyl , Medpace, Medpace, Novo Nordisk, Premier , Sanofi, Stock/Shareholder; Spouse/Partner; Janssen, Merck. L. K. Billings: Advisory Panel; Self; Bayer Inc., Lilly Diabetes, Novo Nordisk, Sanofi. A. Meller donatsky: Employee; Self; Novo Nordisk A/S. M. Frederiksen: Employee; Self; Novo Nordisk A/S. D. C. Klonoff: Consultant; Self; EOFlow, Fractyl Laboratories, Inc., LifeCare, Inc., Novo Nordisk, Roche Diagnostic USA, Samsung, Thirdwayv, Employee; Self; DIabetes Technology Society. E. Parvaresh rizi: Employee; Self; Novo Nordisk. R. M. Bergenstal: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk, Onduo LLC., Roche , Sanofi, United Healthcare , Consultant; Self; Abbott Diabetes, Ascensia , Dexcom, Inc., Eli Lilly and Company, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Other Relationship; Self; HealthPartners Institute, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, NIDDK, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare.FundingNovo Nordisk
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".